PCSK9 Inhibitors May Be Safer Than Statins
A UCLA analysis suggests the cholesterol drugs may carry lower haemorrhagic stroke risk for some patients.
Updated on Nov. 7, 2026 in Stroke
Live Poll
Would you trust a doctor's advice to switch cholesterol medicines after a stroke?
A UCLA study found PCSK9 inhibitors may be a safer cholesterol-lowering option than statins for patients at increased risk of haemorrhagic stroke. The analysis, drawing on 36 completed randomised trials, found statins slightly raise haemorrhagic stroke risk even as they reduce ischaemic stroke risk.
Why it matters
Statins are widely prescribed, with an estimated 7 to 8 million adults taking them across the UK, so a safer alternative for higher-risk patients could influence prescribing decisions. The findings highlight a trade-off between preventing clot-related strokes and the bleeding risk that statins may carry for certain patients.
Patients with a prior ischaemic stroke had a 1.1% chance of haemorrhagic stroke without statins, rising to 1.6% on statins. In those with a prior haemorrhagic stroke, statins raised the risk of future brain bleeds about four times, though the study does not clarify direct comparisons against PCSK9 inhibitors in that group.
The players
University of California, Los Angeles (UCLA)
A public research university in California whose researchers conducted the analysis comparing PCSK9 inhibitors and statins.
The details
Statins block the liver enzyme HMG-CoA reductase, lowering liver cholesterol production, which prompts the liver to pull more LDL cholesterol from the bloodstream. Statins reduce blood clotting, preventing ischaemic strokes, but they do not prevent haemorrhagic strokes, which result from blood vessel rupture rather than clotting.
Timeline
November 2026: Research cited in new publications after release in the journal Stroke.
Health Landscape
The findings extend the evaluation of PCSK9 inhibitors, a drug class that lowers cholesterol as strongly as or more strongly than statins, into the question of stroke safety. They raise the broader question of whether the decades-old statin standard should be re-weighed for patients who already carry a history of stroke.
Patients with a prior stroke or on cholesterol medication may want to discuss with their clinicians whether a PCSK9 inhibitor could be an alternative to statins. Any change in treatment should be guided by a doctor who can weigh individual stroke and bleeding risk.
The takeaway
Cholesterol treatment is not one-size-fits-all, and the balance between preventing clot-related and bleed-related strokes may differ by patient history. Anyone with a prior stroke should review their statin plan with a clinician.
Further reading
For more on the condition at the center of this research, explore our Stroke coverage.
Live Poll
Would you trust a doctor's advice to switch cholesterol medicines after a stroke?
